At end of day Thursday, July 12, the CMS released its proposed Medicare Physician Fee Schedule for 2019. The projected rules update rates and policies applicable to Medicare physicians and other professionals under Medicare, and also include updates to Medicare rates and policies under Part B, as well as to the Quality Payment Program which implements the Merit-Based Incentive Payment System (MIPS) and Alternative Payment Models (APMs).
This is the first year CMS included updates to the Quality Payment Program (QPP) in the proposed fee schedule. This and myriad other changes already have the healthcare industry talking: What do the various changes mean? What is their impact to labs and pathology practices?
Fewer than 165 days remain before your lab will begin to see the financial impact from the new and complicated revisions. To help you and your management team respond in a timely way to these fresh threats, register now to attend “Proposed Changes to the Medicare Physician Fee Schedule and Quality Payment Program Just Released: What You Need to Know and Action Steps to Take Now to Protect Your Lab’s Revenue.” This webinar, taking place Wednesday, August 15 at 2PM EDT, will provide you with an insider’s perspective on the essential market intelligence and knowledge you need to respond to the loss of important revenue that your lab will experience as of January 1.
Absolutely a “must attend” session for pathologists and their laboratory administrators, the webinar is also essential knowledge for all laboratories where Medicare payments are a major source of revenue, and who have a paramount need to maintain the financial solvency of their lab organizations.
The webinar will open with incisive analysis from a foremost expert on this topic, Lâle White, Executive Chairman and CEO, XIFIN, Inc., San Diego, CA. White and her colleagues at XIFIN have access to a remarkable pool of real-world clinical laboratory data, giving White a unique understanding of the subject matter and its potential impact to your laboratory and its financial health, why these changes may be deep and painful to the lab industry as a whole, plus sound recommendations of steps your lab can get started on immediately.
DATE: Wednesday, August 15, 2018
TIME: 2 p.m. EDT; 1 p.m. CDT; 12 p.m. MDT; 11 a.m. PDT
PLACE: Your computer
COST: $195 per dial-in site (unlimited attendance per site) through 8/3/18; $245 thereafter
TO REGISTER: Click here
With your attendance of this webinar, you’ll get the information you need be proactive in your laboratory business, keep your lab profitable, and be armed with the necessary steps you should take to prepare for January 2019. What’s more, for one low price—just $195 (through 8/3/18, $245 thereafter)—you and your entire team at one location can take part in this valuable learning session. Best of all, you’ll be able to ask our speakers your questions on this topic when we open things up for audience Q&A.
Your webinar registration includes:
This timely webinar will help you use the days remaining before the changes take effect to best advantage. Nothing less than the financial health of your pathology practice is at stake—which is why it’s particularly important that you have each and every one of your lab’s management team together to participate.
You can protect your lab’s finances but only if you have the crucial knowledge and information about these proposed changes, in order to prepare the right strategies and action plan.
Executive Chairman and CEO
San Diego, CA
Lâle White is a nationally recognized expert in the field of medical financial management and regulatory compliance, with over 35 years of experience in information systems development and medical billing. She lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the US. She worked with HCFA and the US Office of the Inspector General to develop the first OIG Model Compliance Program. White was previously Vice President – Finance of Laboratory Corporation of America (NYSE: LH), one of the largest clinical reference laboratories in the US, and its predecessor National Health Laboratories (NYSE: NHLI), where she led the software development of several accounts receivable, inventory, cost accounting and financial management systems for the laboratory industry. She previously served on the Board of Directors for bioTheranostics, part of the worldwide bioMerieux group, and is currently a member of the Board of Directors for CombiMatrix Corporation, a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders.